<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256735</url>
  </required_header>
  <id_info>
    <org_study_id>1207.22</org_study_id>
    <nct_id>NCT02256735</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers</brief_title>
  <official_title>A Double-blinded, Randomised, Placebo Controlled, Five-way Crossover Study With One Positive Control (Open-label) (Moxifloxacin) to Assess the Influence of Oral Single Dose KUC 7483 BS (40 mg, 80 mg, 160 mg, 320 mg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the
      ECG in comparison to placebo and moxifloxacin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean time-matched QTcI</measure>
    <time_frame>up to 2 hours following drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean time-matched QTcI</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of uncorrected QT interval</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
    <description>QT interval &lt;=500 ms, &gt; 500 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the QTcI interval</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
    <description>QTcI interval &lt;= 450 ms, &gt;450 ms, &gt;480 ms or &gt;500 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the QTcI interval</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
    <description>QTcI interval &lt; 30 ms, ≤ 60 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Heart Rate (HR)</measure>
    <time_frame>up to 6 hours following drug administration</time_frame>
    <description>increase ≥25 % or decrease HR by ≥25 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-6 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 6 hours)</measure>
    <time_frame>up to 6 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 8 hours) for moxifloxacin</measure>
    <time_frame>up to 8 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 17 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 17 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in 12-lead ECG</measure>
    <time_frame>up to 17 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to 17 days after last drug administration</time_frame>
    <description>Blood pressure, pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>17 days after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>Ritobegron Cl (KUC 7483 CL) tablets low dose</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Ritobegron Cl (KUC 7483 CL) tablets medium 1 dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Ritobegron Cl (KUC 7483 CL) tablets medium 2 dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D</intervention_name>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Ritobegron Cl (KUC 7483 CL) tablets high dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females

          -  Age 30 to 60 years

          -  Body mass index (BMI) within 18.5 to 29.9 kg/m2

          -  In accordance with Good Clinical Practice (GCP) and the local legislation all
             volunteers are to have given their written informed consent prior to admission to the
             study

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders, clinically relevant electrolyte disturbances

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or clinically relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24:00 hours) within at least one month or
             less than ten half-lives of the respective drug before enrolment in the study or
             during the study

          -  Use of any drugs which might influence the results of the trial up to 7 days prior to
             enrolment in the study or during the study

          -  Participation in another trial with an investigational drug (within two months prior
             to administration or during the trial)

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars of &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Drug abuse

          -  Blood donation (&gt; 100 mL within four weeks prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range if indicative of underlying disease
             or poor health

          -  Excessive physical activities within the last week before the trial or during the
             trial

          -  Hypersensitivity to treatment medication, moxifloxacin and/or related drugs of these
             classes

          -  Previous tendon disease related to quinolone treatment

          -  Congenital or documented acquired QT- prolongation, previous history of symptomatic
             arrhythmias

          -  Heart rate at screening of &gt; 80 bpm or &lt; 45 bpm

          -  Any screening ECG value outside of the reference range of clinical relevance
             including, but not limited to Pulse rate (PR) interval &gt; 220 ms, QRS interval &gt; 115
             ms, QTcB &gt; 450 ms, or QT (uncorrected) &gt; 470 ms

        For Female Subjects:

          -  Pregnancy

          -  Positive pregnancy test

          -  No adequate contraception (adequate contraception e.g. sterilization, Intrauterine
             pessary (IUP), oral contraceptives)

          -  Inability to maintain this adequate contraception during the whole study period

          -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>p-Hydroxyamphetamine</mesh_term>
    <mesh_term>Ritobegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

